RSM logo
JRSM

Home Current issue Browse archive Alerts About the journal Feedback
 
J R Soc Med 1987;80:91-93
© 1987 Royal Society of Medicine

This Article
Right arrow Send a Quick Comment
Right arrow Alert me when this article is cited
Right arrow Alert me when Quick Comments are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Plaut, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of the Royal Society of Medicine, Vol 80, Issue 2 91-93, Copyright © 1987 by Royal Society of Medicine

ORIGINAL ARTICLES

Effectiveness of amantadine in reducing relapses in multiple sclerosis

GS Plaut

Fifty-three patients with multiple sclerosis were assessed in a double-blind multicentre study for the effect of amatadine. The patients were observed in general practices for up to four years. Relapses occurred in 5 of the 24 patients treated with amantadine and in 14 of the 29 placebo-treated patients. Neurological deterioration was not significantly different in the two groups.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
D. Centonze, L. Muzio, S. Rossi, F. Cavasinni, V. De Chiara, A. Bergami, A. Musella, M. D'Amelio, V. Cavallucci, A. Martorana, et al.
Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis
J. Neurosci., March 18, 2009; 29(11): 3442 - 3452.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan, F. Fezza, V. De Chiara, L. Battistini, G. Bernardi, S. Bernardini, et al.
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis
Brain, October 1, 2007; 130(10): 2543 - 2553.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. R. Kanwar, R. K. Kanwar, and G. W. Krissansen
Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis
Brain, June 1, 2004; 127(6): 1313 - 1331.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
G. A. Rosenberg and O. Appenzeller
Amantadine, Fatigue, and Multiple Sclerosis
Arch Neurol, October 1, 1988; 45(10): 1104 - 1106.
[Abstract] [PDF]



  RSM Press eJournals Collection 2010